Replies to post #163853 on Biotech Values

[mcbio]

You are right. Since we were talking about GT1 and GT3 within the new 3B study I was thinking about the design of the GT1 study.

GT1 is still the biggest piece of the HCV pie and I still don't get why GILD would expand to 16 and 24-week trials in GT1 if the other trial they are running of 8 and 12-weeks would otherwise suffice. This is a Phase 3b but both safety and efficacy are being measured. Why need to measure for efficacy for 16 and 24-weeks if 8 and 12 was sufficient from other trial with GT1 patients? Doesn't make sense to me.